Janus Henderson Investors US’s Avadel Pharmaceuticals AVDL Stock Holding History

Janus Henderson Investors US’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$21M	Sell	2,166,766 -61,039	-3%	-$610K	0.02%	605
2016 Q4	$23.1M	Buy	2,227,805 +42,969	+2%	+$472K	0.02%	589
2016 Q3	$27.1M	Sell	2,184,836 -12,568	-0.6%	-$164K	0.02%	543
2016 Q2	$25.6M	Buy	2,197,404 +1,903,256	+647%	+$20.3M	0.02%	534
2016 Q1	$3.25M	Sell	294,148 -4,024,167	-93%	-$40M	﹤0.01%	840
2015 Q4	$52.7M	Sell	4,318,315 -23,200	-0.5%	-$362K	0.04%	401
2015 Q3	$70.8M	Buy	4,341,515 +755,481	+21%	+$16.6M	0.06%	347
2015 Q2	$76M	Buy	3,586,034 +603,182	+20%	+$10.8M	0.06%	357
2015 Q1	$53.6M	Buy	+2,982,852	New	+$46.7M	0.04%	437

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Janus Henderson Investors US's AVDL Position: Q1 2017 in Review

Janus Henderson Investors US reduced its Avadel Pharmaceuticals (AVDL) stake by 2.7% in Q1 2017, selling an estimated $610K and leaving 2,166,766 shares worth $21M. The position accounts for 0.02% of the portfolio, ranked #605.

Janus Henderson Investors US first reported a position in AVDL in Q1 2015 and has held it in 9 quarters since. The position peaked at $76M in Q2 2015. 74 funds tracked by Wall St. Rank hold AVDL as of Q1 2017.

Janus Henderson Investors US held 2,166,766 shares of Avadel Pharmaceuticals worth $21M as of Q1 2017.
Janus Henderson Investors US sold 61,039 Avadel Pharmaceuticals shares in Q1 2017, an estimated $610K.
Avadel Pharmaceuticals made up 0.02% of Janus Henderson Investors US's portfolio in Q1 2017, its #605 holding.
Janus Henderson Investors US first reported a position in Avadel Pharmaceuticals in Q1 2015 and has held it in 9 quarters since.
Janus Henderson Investors US's Avadel Pharmaceuticals position peaked at $76M in Q2 2015.
74 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2017.

Based on Janus Henderson Investors US's 13F filing for Q1 2017, filed 16 May 2017.